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Growth factors and mitogens use the Ras/Raf/MEK/ERK signaling cascade to transmit signals from their receptors to regulate gene expression
and prevent apoptosis. Some components of these pathways are mutated or aberrantly expressed in human cancer (e.g., Ras, B-Raf). Mutations also
occur at genes encoding upstream receptors (e.g., EGFR and Flt-3) and chimeric chromosomal translocations (e.g., BCR-ABL) which transmit their
signals through these cascades. Even in the absence of obvious genetic mutations, this pathway has been reported to be activated in over 50% of acute
myelogenous leukemia and acute lymphocytic leukemia and is also frequently activated in other cancer types (e.g., breast and prostate cancers).
Importantly, this increased expression is associated with a poor prognosis. The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt pathways interact with
each other to regulate growth and in some cases tumorigenesis. For example, in some cells, PTENmutation may contribute to suppression of the Raf/
MEK/ERK cascade due to the ability of activated Akt to phosphorylate and inactivate different Rafs. Although both of these pathways are commonly
thought to have anti-apoptotic and drug resistance effects on cells, they display different cell lineage specific effects. For example, Raf/MEK/ERK is
usually associated with proliferation and drug resistance of hematopoietic cells, while activation of the Raf/MEK/ERK cascade is suppressed in some
prostate cancer cell lines which have mutations at PTEN and express high levels of activated Akt. Furthermore the Ras/Raf/MEK/ERK and Ras/
PI3K/PTEN/Akt pathways also interact with the p53 pathway. Some of these interactions can result in controlling the activity and subcellular
localization of Bim, Bak, Bax, Puma and Noxa. Raf/MEK/ERK may promote cell cycle arrest in prostate cells and this may be regulated by p53 as
restoration of wild-type p53 in p53 deficient prostate cancer cells results in their enhanced sensitivity to chemotherapeutic drugs and increased
expression of Raf/MEK/ERK pathway. Thus in advanced prostate cancer, it may be advantageous to induce Raf/MEK/ERK expression to promote
cell cycle arrest, while in hematopoietic cancers it may be beneficial to inhibit Raf/MEK/ERK induced proliferation and drug resistance. Thus the Raf/
MEK/ERK pathway has different effects on growth, prevention of apoptosis, cell cycle arrest and induction of drug resistance in cells of various
lineages which may be due to the presence of functional p53 and PTEN and the expression of lineage specific factors.
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1.1. Overview of the Ras/Raf/MEK/ERK signaling
The Ras/Raf/MEK/ERK cascade couples signals from cell
surface receptors to transcription factors, which regulate gene
expression. Furthermore, this cascade also regulates the activity
of many proteins involved in apoptosis. A diagrammatic
overview of the Ras/Raf/MEK/ERK pathway is presented in
Fig. 1. This pathway is often activated in certain tumors by
chromosomal translocations such as BCR-ABL, mutations in
cytokine receptors such as Flt-3, Kit, Fms or overexpression of
wild type or mutated receptors, e.g., EGFR. The Raf/MEK/ERK
pathway also has profound effects on the regulation of apoptosis
by the post-translational phosphorylation of apoptotic regula-
tory molecules including Bad, Bim, Mcl-1, caspase 9 and more
controversially Bcl-2. This pathway has diverse effects which
can regulate cell cycle progression, apoptosis or differentiation
[1]. A survey of the literature documents the daily increase in
the complexity of this pathway, as there are multiple members
of the kinase, transcription factor, apoptotic regulator and
caspase executioner families, which can be activated orFig. 1. Overview of Raf/MEK/ERK Pathway. The Raf/MEK/ERK pathway is regula
residues on Raf. Some of these phosphorylation events serve to enhance Raf activity
(shown by a white P in a black circle. Moreover there are phosphatases such as PP
transcription factors regulated by this pathway are indicated in diamond shaped outinactivated by protein phosphorylation. Furthermore, this
pathway can induce the transcription of certain genes. Raf,
either through downstream MEK and ERK, or independently of
MEK and ERK, can induce the phosphorylation of proteins,
which control apoptosis. Additional signal transduction path-
ways interact with the Raf/MEK/ERK pathway to positively or
negatively regulate its activity. Abnormal activation of this
pathway occurs in human cancer due to mutations at upstream
membrane receptors, Ras and B-Raf as well as genes in other
pathways (e.g., PI3K, PTEN, Akt), which serve to regulate
Raf activity. The Raf/MEK/ERK pathway also influences
chemotherapeutic drug resistance as ectopic activation of Raf
induces resistance to doxorubicin and paclitaxel in breast
cancer cells. Mutations at B-Raf have been frequently de-
tected in some malignancies including melanoma and thyroid
cancers [2]. For all the above reasons, the Raf/MEK/ERK
pathway is an important pathway to target for therapeutic
intervention. Inhibitors of Ras, Raf, and MEK and some
downstream targets have been developed and many are
currently in clinical trials. Naturally, some inhibitors are better
than others and certain “specific” inhibitors may inhibit multiple
kinases.ted by Ras as well as various kinases, which serve to phosphorylate S/T and Y
(shown by a black P in a white circle) whereas others serve to inhibit Raf activity
2A, which remove phosphates on certain regulatory residues. The downstream
lines.
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cascade
Ras is a small GTP-binding protein, which is the common
upstream molecule of several signaling pathways including Raf/
MEK/ERK, PI3K/Akt and RalEGF/Ral [3]. Four Ras proteins
have been identified, namely Ha-Ras, N-Ras, Ki-Ras 4A and
Ki-Ras 4B. The 2 isoforms of Ki-Ras are produced from the
same gene by alternative splicing. Ras proteins show varying
abilities to activate the Raf/MEK/ERK and PI3K/Akt cascades.
They may differ in terms of their potency to activate the Raf/
MEK/ERK cascade with Ki-Ras being a stronger induce of Raf/
MEK/ERK than Ha-Ras [4]. In contrast, Ha-Ras may be a
stronger inducer of PI3K/Akt than Raf/MEK/ERK. Different
mutation frequencies have been observed between Ras genes in
human cancer and it is important to realize that Ki-Ras is the
more frequently mutated Ras isoform in human cancer,
although in some particular cancer subsets N-Ras may be
more frequently mutated.
For Ras to be targeted to the cell membrane, it must be
farnesylated by farnesyl transferase (Ha-, Ki-, and N-Ras) or
geranylgeranylated by geranylgeranyl transferase (N- and Ki-
Ras). Farnesylation and geranylgeranylation both occur on the
same cysteine residue. Ras preferentially undergoes farnesyla-
tion, however, in the presence of farnesylation inhibitors, N-Ras
and Ki-Ras can undergo gernylgernylation. Ha-Ras and N-Ras
can also undergo palmitoylation with Ha-Ras having two
palmitoylation sites and N-Ras having one palmitoylation site.
Ki-Ras appears to lack a palmitoylation site. It is believed that
palmitoylation has a role in plasma membrane microlocaliza-
tion. These post-translational modifications are important as
they represent sites for therapeutic intervention which will be
discussed later.
Following binding of cytokines, growth factors or mitogens
to their appropriate receptors, activation of the coupling
complex Shc/Grb2/SOS occurs. Upon stimulation by Shc/
Grb2/SOS, the inactive Ras exchanges GDP for GTP and
undergoes a conformational change and becomes active. The
GTP bound active Ras can then recruit Raf to cell membrane.
Ras is frequently mutated in human cancer and these point
mutations occur in condons 12, 13, 59, and 61 [1]. These
mutations result in the constitutive activation of the protein
which no longer requires ligand for activation.
1.3. Complex activation and inactivation of Raf by
phosphorylation
The mammalian Raf gene family consists of A-Raf, B-Raf
and Raf-1 (C-Raf). Raf is a serine/threonine (S/T) kinase and
is normally activated by a complex series of events including:
(i) recruitment to the plasma membrane mediated by an
interaction with Ras [4]; (ii) dimerization of Raf proteins [5];
(iii) phosphorylation/dephosphorylation on different domains
[6]; (iv) disassociation from the Raf kinase inhibitory
protein (RKIP) [7,8] and (v) association with scaffolding
complexes (e.g., kinase suppressor of Ras, (KSR) [9–11].
Raf activity is further modulated by chaperonin proteinsincluding Bag1, 14-3-3 [12] and heat shock protein 90 (Hsp90)
[13].
There are at least thirteen regulatory phosphorylation sites on
Raf-1 [1]. Some of these sites [e.g., S43, S259 and S621] are
phosphorylated when Raf-1 is inactive. This allows 14-3-3 to
bind Raf-1 and confer a configuration which is inactive. Upon
cell stimulation, S621 becomes transiently dephosphorylated by
an unidentified phosphatase. Phosphatases such as protein
phosphatase 2A (PP2A) dephosphorylate S259 [8]. 14-3-3 then
disassociates from Raf-1. This allows Raf-1 to be phosphory-
lated at S338, Y340, and Y341, rendering Raf-1 active. A Src
family kinase is likely responsible for phosphorylation at Y340
and Y341 [14]. Thus a side effect of Src family kinase inhibitors
such as Dasatinib, which is being used to treat certain Imatinib
resistant chronic myeloid leukemia (CML) patients and other
cancer patients who overexpresses mutant c-Kit [15,16] would
be suppression of Raf-1/MEK/ERK signaling in certain cells.
This may be a desired or undesired side effect.
Y340 and Y341, the phosphorylation targets of Src family
kinases, are conserved in A-Raf (Y299 and Y300), but are
replaced with aspartic acid (D) at the corresponding positions in
B-Raf (D492 and D493) [6,14]. The negatively charged aspartic
acid residues mimic activated residues, which confers elevated
basal activity to B-Raf. Maximal activation of Raf-1 and A-Raf
requires both Ras and Src activity while B-Raf activation is Src-
independent [14]. Interestingly, as will be discussed later, a
greater number of mutations are detected at B-Raf than either
Raf-1 or A-Raf, in human cancer. This may have resulted from a
simpler mode of activation and selection of cells containing B-
Raf mutations. Dasatinib would be predicted to not inhibit B-
Raf signaling, however, the story may be more complex as in
some scenarios B-Raf signals through B-Raf: Raf-1 hetero-
dimers [2]. Whether this B-Raf:Raf-1 heterodimers require
phosphorylation at Y340 and Y341 for activation is unclear.
The S338 residue present in Raf-1 is conserved among the
three Raf isoforms, however, in B-Raf (S445), this correspond-
ing site is constitutively phosphorylated [17] S338 phosphor-
ylation on Raf-1 is stimulated by Ras and is dependent on p21-
activated protein kinase (PAK) [18]. Other phosphorylation
sites in Raf-1 that may modulate its activity include: S43, S339,
T491, S494, S497, S499, S619 and S621. Protein kinase C
(PKC) has been shown to activate Raf and induce cross-talk
between PKC and Raf/MEK/ERK signaling pathways [19].
S497 and S499 were identified as the target residues on Raf-1
for PKC phosphorylation. However, other studies suggest that
these sites are not necessary for Raf-1 activation [20].
Raf activity is negatively regulated by phosphorylation on the
conserved region (CR)2 regulatory domain. Akt and protein
kinase A (PKA) phosphorylate S259 on Raf-1 and inhibit its
activity [21]. Furthermore, Akt or the related serum/glucocorti-
coid regulated kinase (SGK) phosphorylate B-Raf on S364 and
S428 and inactivate its kinase activity [22,23]. These S-
phosphorylated Rafs associate with 14-3-3 and become inactive.
The scaffolding protein RKIP has been shown to inhibit Raf-
1 activation and downstream signaling [7,24]. RKIP is a
member of the phosphatidylethanolamine-binding protein
(PEBP) family. This multi-gene family is evolutionarily
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animals [24]. Interesting RKIP can bind either Raf or MEK/
ERK but not to Raf, MEK and ERK all together. Various
isoforms of PKC have been shown to phosphorylate RKIP on
S153 which results in the disassociation of Raf and RKIP. The
role of RKIP in metastasis will be discussed later.
Hsp90 may serve to stabilize activated Raf. Drugs such as
geldanamycin inhibit Hsp90 and result in the rapid degradation
of Raf [13]. Although Raf is a target of these drugs, they are
relatively non-specific and also result in the degradation of Src,
EGFR, HER2, CDK4 and Akt. Raf is also a target of caspases.
In this case, Raf is degraded and the cycle of Raf activation and
inactivation by kinases and phosphatases is irreversibly broken.
The importance of Raf-1 in the Raf/MEK/ERK signal
transduction pathway has come into question due to the
discovery that B-Raf was a much more potent activator of
MEK compared to Raf-1 and A-Raf. Many of the “functions” of
Raf-1 persist in Raf-1 knock-out mice, and are likely maintained
by endogenous B-Raf [25]. Interestingly and controversially it
was recently proposed that B-Raf is not only the major activator
of MEK1, but B-Raf is also involved in Raf-1 activation. B-Raf
may be temporally activated before Raf-1. However, there may
be different subcellular localizations of B-Raf and Raf-1 within
the cell that exert different roles in signaling and apoptotic
pathways [26]. In some cases, B-Raf may transduce its signal
through Raf-1 and B-Raf can form heterodimers with Raf-1.
Dimerization is one important component involved in Raf
activation [27,28]. The reasons for these added complexities in
the Raf/MEK/ERK kinase cascade are not obvious but may
represent another layer of fine-tuning. Alternatively, B-Raf:Raf-
1 heterodimers may have different substrate specificities or
affinities than B-Raf:B-Raf and Raf-1:Raf-1 homodimers.
Furthermore, as will be discussed later, some B-Raf mutants
which are kinase deficient may transmit their signals via
forming heterodimers with Raf-1 [2].
1.4. Activation of MEK1 by Raf
Mitogen-activated protein kinase/ERK kinase (MEK1) is a
tyrosine (Y-) and S/T-dual specificity protein kinase [29]. Its
activity is positively regulated by Raf phosphorylation on S
residues in the catalytic domain. All three Raf family members
are able to phosphorylate and activate MEK but different
biochemical potencies have been observed (B-Raf>Raf-1≫A-
Raf) [29]. Activated MEK1 mutants have been constructed
which will abrogate the cytokine-dependence of hematopoietic
cells and morphologically transform NIH-3T3 cells [30].
Another interesting aspect regarding MEK1 is that its
predominate downstream target is ERK. In contrast, down-
stream ERK has multiple targets. Thus, therapeutic targeting of
MEK1 is relatively specific.
1.5. Activation of ERK1,2 by MEK1 and downstream targets of
ERKs
Extracellular-signal-regulated kinases 1,2 (ERK), are S/T
kinases and their activities are positively regulated by phos-phorylation mediated by MEK1 and MEK2. ERKs can directly
phosphorylate many transcription factors including Ets-1, c-Jun
and c-Myc. ERK can also phosphorylate and activate the 90 kDa
ribosomal S6 kinase (p90Rsk), which then leads to the activation
of the transcription factor CREB [1] (see Fig. 1). Moreover,
through an indirect mechanism, ERK can lead to activation of
the NF-κB transcription factor (nuclear factor immunoglobulin
κ chain enhancer-B cell) by phosphorylating and activating
inhibitor κB kinase (IKK) [31,32]. ERK1 and ERK2 are
differentially regulated. These are only a few examples of the
downstream targets of ERK 1,2. ERK has many other targets
(over 160). ERK can enter the nucleus to phosphorylate many
transcription factors [1]. ERK can also phosphorylate many
proteins involved in cell cycle regulation as will be discussed
later. ERK2 has been positively associated with proliferation
while ERK1 may inhibit the effects of ERK2 in certain cells
[33].
1.6. Activation of the Raf/MEK/ERK pathway by oxidative
stress
Reactive oxygen species (ROS) are well known to
induce the activation of the Raf/MEK/ERK signaling
pathways. Oxidative stress-induced ERK1/2 activation is
reported in a variety of cell types [34–42]. In some cases
reactive oxygen intermediates act directly on growth recep-
tors, such as the EGFR, in a ligand-independent fashion
and induce the activation of Ras and ERK1/2 signaling
[43]. This type of responsiveness does not appear to be
limited to the EGFR as ROS will also induce the ligand-
independent activation of the platelet derived growth factor
(PDGF) receptor and a subsequent increase in both Ras and
ERK1/2 activity [43]. Ligand-independent receptor activa-
tion is not the only mechanism by which oxygen radicals
activate the ERK1/2 signaling pathway. ROS mediate
activation of Ras independently of reactive oxygen inter-
mediate-induced receptor activation [44]. Furthermore, Ras
expression is not an absolute requirement for ROS
activation of the ERK1/2 signaling pathway either. ROS
will induce the activation of the ERK1/2 signaling pathway
in Ras negative cells [45]. This may occur in part via c-Src
as c-Src can phosphorylate and activate phospholipase C
(PLC)-gamma [46]. Activation of PLC-gamma results in the
generation of diacyl-glycerol (DAG) and increases in
intracellular calcium which in turn induce activation of
several forms of PKC. Although PKC can lead to Ras
activation it has also been shown to directly activate Raf
[47]. Furthermore, ROS inhibit protein phosphatases [48,49]
and inhibition of phosphatase activity results in the
activation of the ERK1/2 signaling pathways [50]. Thus, it
would appear that the ERK1/2 kinase signaling cascade can
be activated at multiple points by ROS. It should be noted,
however, that the MEK1 and 2 inhibitors U0126 and
PD98059 both block oxidative stress-induced ERK1/2 activa-
tion [51,52] indicating that activating actions of oxidative
stress do not occur directly on ERK1/2 but instead are
localized at upstream targets.
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the ERK family member ERK5/Big Map Kinase (BMK) in
human skin fibroblasts, human vascular smooth muscle cells,
and human umbilical vein endothelial cells [53]. In PC12 cells,
hydrogen peroxide-induced ERK5/BMK1 activation requires
the activation of a Src kinase [54]. Superoxide anion may have a
role in ERK5/BMK1 activation as superoxide scavengers
prevented Angiotensin II- and endothelin-1-induced ERK5/
BMK1 phosphorylation.
ROS such as, singlet oxygen [55–57], hydrogen peroxide
[58], nitric oxide [44,59], and peroxynitrite [60] induce the
activation of the stress activated or JNK and p38 pathways.
Activation of the JNK pathway by reactive oxygen inter-
mediates likely occurs through the apoptosis signal related
kinase (ASK1) and MEKK1 [61–64]. Reduced thioredoxin
[62,63] binds to the N-terminal of ASK1 and inhibits ASK1
activity. Upon an oxidative stress, thioredoxin becomes oxi-
dized and disassociates from ASK1; allowing ASK1 to
oligomerize, autophosphorylate, and become activated [64].
Reactive nitrogen containing species can have multiple effects
on ASK1 activation. First, reactive nitrogen species are able to
nitrosylate thioredoxin and prevent thioredoxin binding to
ASK1 [65]. This mechanism favors the activation of ASK1. The
mechanism by which reactive oxygen intermediates induce the
p38 pathway very likely occurs via mechanisms similar to the
JNK pathway (i.e. Ask1). Many of the same signals activate
both pathways concurrently and in many of the same cell types
[62,64].Fig. 2. MEK1/ERK Independent Effects of Raf-1. Many other non-MEK1/ERK med
cell cycle regulatory, anti-apoptotic effects on NF-κB activation) may be more likely
Raf-1 activity and thus have anti-apoptotic and cell cycle effects. Raf can activate th1.7. Non-MEK/ERK mediated functions of Raf-1
Raf-1 has also been proposed to regulate apoptosis at the
mitochondrial membrane [67]. Expression of membrane
targeted Raf was shown to complement a BCR-ABL mutant
in abrogating the cytokine-dependence of hematopoietic cells
[66–68] (see Fig. 2). In these mutant BCR-ABL transfected
cells, Bad was expressed in the hyperphosphorylated inactive
form and released from the mitochondria into the cytosol. In
contrast, in the cells containing the BCR-ABL mutant but
lacking the membrane-targeted Raf-1, which were not
cytokine-dependent, Bad was hypophosphorylated and present
in the mitochondrial fraction. BCR-ABL may interact with
mitochondrial targeted Raf-1 to alter the phosphorylation of
Bad at the mitochondrial membrane and hence regulate
(prevent) apoptosis in hematopoietic cells containing the
BCR-ABL chromosomal translocation [69]. This survival
mechanism was independent of MEK and ERK.
1.8. Effects of Ras/Raf/MEK/ERK signaling on cell cycle
progression
Ras and its downstream effectors alter the expression of
many molecules which regulate cell cycle including p16Ink4a,
p15Ink4b and p21Cip1, and can lead to premature cell cycle arrest
at the G1 phase. This p15Ink4b/p16Ink4a or p21Cip1-mediated
premature G1 arrest and subsequent senescence is dependent on
the Raf/MEK/ERK pathway [9,70,71].iated functions of Raf-1 have been postulated. Some of the purported roles (e.g.,
than others (e.g., effects of Raf-1 on p53 transcription). BCR-ABL can activate
e Cdc25 phosphatase which results in CDK activation.
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such divergent responses as cell growth, cell cycle arrest or
even apoptosis [70,72,73]. The fate of the cells depends on
the level and isoform of Raf kinase expressed. Ectopic
overexpression of Raf proteins is associated with cell
proliferation in cells including hematopoietic cells [74];
erythroid progenitor cells [75]; and A10 smooth muscle
cells [76]. However, overexpression of activated Raf proteins
is associated with cell cycle arrest in rat Schwann cells,
mouse PC12 cells, human promyelocytic leukemia HL-60
cells, small cell lung cancer cell lines, prostate cancer LNCaP
cells, and some hematopoietic cells [77–79]. Depending on
the Raf isoform, overexpression of Raf can lead to cell
proliferation (A-Raf or Raf-1) or cell growth arrest (B-Raf) in
NIH-3T3 fibroblast and FDC-P1 hematopoietic cells [70–
73,80,81]. It is not clear why overexpression of the Raf gene
can lead to such conflicting results, but it has been suggested
that the opposite outcomes may be determined by the amount
or activity of the particular Raf oncoprotein [70,81].
NIH-3T3 cells have been transfected with the three
different Raf genes. The introduced A-Raf molecule was
able to upregulate the expression of cyclin D1, cyclin E, Cdk2,
and Cdk4 and down-regulate the expression of Cdk inhibitor
p27Kip1 [80]. These changes induced the cells to pass through
G1 phase and enter S phase. It should be remembered that
A-Raf is the weakest Raf kinase and its role in cell
proliferation is not clear. However, in B-Raf and Raf-1
transfected NIH-3T3 cells, there was also a significant induc-
tion of p21Cip1, which led to G1 arrest. Using cytokine-
dependent FDC-P1 hematopoietic cells transfected with
conditionally-active mutant Raf-1, A-Raf and B-Raf genes as
a model, we have demonstrated that moderate Raf activation,
such as A-Raf and Raf-1, led to cell proliferation, which was
associated with the induction of cyclin expression and Cdk
activity. However, ectopic expression of the much more potent
B-Raf led to apoptosis [70,81].
An alternative explanation for the diverse proliferative
results obtained with the three Raf genes is the different
biological effects of A-Raf, B-Raf, and Raf-1. The individual
functions of these three different Raf proteins are not fully
understood. Even though it has been shown that all three Raf
proteins are activated by oncogenic Ras, target the same
downstream molecules, i.e. MEK1 and MEK2, and use the
same adapter protein for conformational stabilization; differ-
ent biological and biochemical properties among them have
been reported and their functions are not always compensa-
table [82–85]. It is safe to say that even as we learn more
about the intricacies of these Raf molecules, we discover that
there are more questions regarding their specificities and
mechanisms by which they exert their effects on cell
proliferation.
1.9. Regulation of apoptosis by the Raf/MEK/ERK cascade
Clearly Raf has many roles in kinase cascades and down-
stream transcription factors which regulate apoptosis. The Raf/
MEK/ERK cascade and Raf by itself also have diverse effectson key molecules involved in the prevention of apoptosis. For
many years now, it has been known that the Raf/MEK/ERK
pathway can phosphorylate Bad on S112 which contributes to
its inactivation and subsequent sequestration by 14-3-3 proteins
[86]. This allows Bcl-2 to form homodimers and an anti-
apoptotic response is generated. Activation of the Raf/MEK/
ERK cascade can also result in the phosphorylation of the anti-
apoptotic Mcl-1 protein and the pro-apoptotic Bim protein.
Phosphorylation of Bim results in its disassociation from Bcl-2,
Bcl-XL, and Mcl-1 and Bim becomes ubiquitionated and
targeted to the proteosome. This allows Bcl-2, Bcl-XL and Mcl-
1 to bind Bax and prevent Bax activation and the formation of
Bax:Bax homodimers. Thus apoptosis is inhibited [87–89].
ERK phosphorylation of Bim on S69 can result in ubiquitina-
tion of Bim and subsequent proteosomal degradation [90]. Bim
can also be phosphorylated by Akt at S87 and this also
attenuates Bim's apoptotic potential and promotes binding to
14-3-3 proteins [91]. In contrast, phosphorylation of Bim at S65
by JNK can result in apoptosis due to stimulation of Bax:Bax
interactions [92,93]. JNK also phosphorylates 14-3-3 family
members which allow translocation of Bax from the cytosol to
the mitochondria membrane where it can promote apoptosis
[94]. Clearly depending upon the particular residues that Bim is
phosphorylated can influence whether a cell undergoes
apoptosis or survives.
Recently it has been shown that the Raf/MEK/ERK cascade
can phosphorylate caspase 9 on residue T125 which con-
tributes to the inactivation of this protein [95]. Interestingly,
both Bad and caspase 9 are also phosphorylated, by the Akt
pathway indicating that the Raf/MEK/ERK and PI3K/Akt
pathways can cross-talk and result in the prevention of
apoptosis [96]. However, the significance of caspase 9
phosphorylation by Akt is controversial, as this phosphoryla-
tion site is not evolutionally conserved. More controversially,
Bcl-2 is also phosphorylated by the Raf/MEK/ERK cascade
on certain residues, in the loop region, which has been
associated with enhanced anti-apoptotic activity [97,98]. As
noted earlier, Raf-1 has MEK- and ERK-independent func-
tions at the mitochondrial membrane by phosphorylating Bad,
which results in its disassociation from the mitochondrial
membrane.
Recently Raf-1 was shown to interact with mammalian
sterile 20-like kinase (MST-2) and prevent its dimerization
and activation [99]. MST-2 is a kinase, which is activated by
pro-apoptotic agents such as staurosporine and Fas ligand.
Raf-1 but not B-Raf binds MST-2. Depletion of MST-2 from
Raf-1−/− cells abrogated sensitivity to apoptosis. Overexpres-
sion of MST-2 increased sensitivity to apoptosis. It was
proposed that Raf-1 might control MST-2 by sequestering it
into an inactive complex. This complex of Raf-1:MST-2 is
independent of MEK and downstream ERK. Raf-1 can also
interact with the ASK1 to inhibit apoptosis [100]. ASK1 is a
general mediator of apoptosis and it is induced in response to
a variety of cytotoxic stresses including TNF, Fas and ROS.
ASK1 appears to be involved in the activation of the JNK and
p38 MAP kinases. This is another interaction of Raf-1 which
is independent of MEK and ERK.
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A common feature of cells transformed by Raf is the
expression of growth factors, which often have autocrine
effects. NIH-3T3 cells transformed by activated Raf secrete
heparin binding epidermal growth factor (hbEGF) [101].
Hematopoietic cells transformed by activated Raf genes often
express granulocyte macrophage-colony stimulating factor
(GM-CSF), which has autocrine growth factor effects
[72,102–104]. Kaposi's sarcoma transformed B cells, which
express elevated levels of B-Raf, express high levels of vascular
endothelial growth factor (VEGF) [105]. Recently it has been
shown that B-Raf increases the infectivity of Kaposi's Sarcoma
Virus [106]. One mechanism responsible for this enhancement
of viral infection by B-Raf is its ability to induce VEGF
expression [107–109]. Many growth factor genes contain in
their promoter regions binding sites for transcription factors
phosphorylated by the Raf/MEK/ERK pathway [11]. Thus
aberrant Raf expression may establish an autocrine loop, which
results in the continuous stimulation of cell growth. Alter-
natively, the VEGF expression induced by Raf can promote
angiogenesis. Raf-induced growth factor expression will
contribute to both the prevention of apoptosis as well as
chemotherapeutic drug resistance as growth factor expression
has been associated with both the prevention of apoptosis and
drug resistance [110].
1.11. The PI3K/PTEN/Akt pathway and its role in regulating
Raf/MEK/ERK
After ligand induced activation of specific receptors, PI3K
can be activated by two mechanisms. First, a phosphorylated Y
residue on the receptor serves as a docking site for the p85
regulatory subunit of PI3K [111]. This recruits the catalytic
subunit of PI3K, p110, to this complex. Alternatively, upon
activation of the cytokine receptor by the appropriate ligand, the
Shc protein binds the receptor to enable the Grb-2 and Sos
proteins to form a complex which results in the activation of
Ras. Ras is then able to induce the membrane translocation and
activation of the p110 subunit of PI3K.
Activated PI3K converts phosphatidylinositol 4,5 bipho-
sphate (PIP2) into phosphatidylinositol 3,4,5 phosphate (PIP3)
which results in the membrane localization of phosphoinositol-
dependent kinase-1 (PDK1) via its pleckstrin homology (PH)
domain. Akt is also recruited to the lipid-rich plasma membrane
by its PH domain and is phosphorylated at residues by T308 and
S473 by PDK1 and an unidentified kinase, respectively. An
overview of the PI3K/Akt pathway is presented in Fig. 3.
Akt is the primary mediator of PI3K-initiated signaling; it
has a number of downstream substrates. Among these targets
are: Bad, Bim, procaspase-9, IκKalpha, the forkhead family
of transcription factors (FKHR/AFX now called FOXO3a),
GSK-3β, MDM-2, p21CIP1, p27KIP1 and others [91,111,112].
It is worth noting that Akt can cause the activation of specific
substrates (e.g., IκKalpha and CREB) or may mediate the
inactivation of other proteins (e.g., Raf, B-Raf [by the Aktrelated kinase SGK], p21Cip-1, Bim, Bad, procaspase-9,
FOXO3a, and GSK-3β).
In addition, this pathway also includes phosphatases that
serve to negatively regulate the growth-promoting effects of
PI3K activity. The phosphatases PTEN and SHIP-1/2 can
remove the phosphates from PIP3 [113]. Mutations in these
phosphatases, which eliminate their activity, can lead to tumor
progression. Consequently, the genes encoding these phospha-
tases are referred to as anti-oncogenes or tumor suppressor
genes.
1.12. Ras/Raf/MEK/ERK and human cancer
Amplification of ras proto-oncogenes and activating muta-
tions that lead to the expression of constitutively-active Ras
proteins are observed in approximately 30% of human cancers
[114,115]. B-Raf has been reported to be mutated in approxi-
mately 7% of all cancers [2]. However, this frequency may
change as more and diverse tumors are examined for B-Raf
mutation. Recent studies indicated that mutated alleles of Raf-1
are present in therapy induced acute myelogenous leukemia
(t-AML) [116]. These leukemias arose after chemotherapeutic
treatment of breast cancer patients. The mutated Raf-1 genes
detected were transmitted in the germ line, thus they are not a
spontaneous mutation in the leukemia but may be associated
with the susceptibility to induction of t-AML in these Austrian
breast cancer patients.
For many years, the Raf oncogenes were not thought to be
frequently mutated in human cancer and more attention to
abnormal activation of this pathway was dedicated to Ras
mutations which can regulate both the Raf/MEK/ERK and
PI3K/Akt pathways. However, recently it was shown that B-Raf
is frequently mutated in certain types of cancer, especially
melanoma (27 to 70%), papillary thyroid cancer (36 to 53%),
colorectal cancer (5 to 22%) and ovarian cancer (30%) [2,117–
119]. The reasons for mutation at B-Raf and not Raf-1 or A-Raf
in melanoma patients are not entirely clear. Based on the
mechanism of activation of B-Raf, it may be easier to select for
B-Raf than either Raf-1 or A-Raf mutations. As stated
previously, activation of B-Raf would require one genetic
mutation whereas activation of either Raf-1 or A-Raf needs two
genetic events. It has been proposed recently that the structure
of B-Raf, Raf-1 and A-Raf may dictate the ability of activating
mutations to occur at these molecules, which can permit the
selection of oncogenic forms [2,119,120]. These predictions
have arisen from determining the crystal structure of B-Raf
[120]. Like many enzymes, B-Raf is proposed to have small and
large lobes, which are separated, by a catalytic cleft. The
structural and catalytic domains of B-Raf and the importance of
the size and positioning of the small lobe may be critical in its
ability to be stabilized by certain activating mutations. In
contrast, the precise substitutions in A-Raf and Raf-1 are not
predicted to result in small lobe stabilization thus preventing the
selection of mutations at A-Raf and Raf-1, which would result
in activated oncogenes [120]. Raf-1 has been known for
years to interact with Hsp90. Hsp90 may stabilize activated
Raf-1, B-Raf and A-Raf. The role that Hsp90 plays in
Fig. 3. Overview of the PI3K/Akt Pathway. The PI3K/Akt pathway is activated either by the p85 PI3K regulatory subunit binding to an activated tyrosine residue on
the activated growth factor receptor or via interaction with Ras. Both result in the membrane localization of PI3K. Some of the downstream effects of activation of
PI3K pathway are shown. PIP2 is phosphorylated by PI3K to create PIP3 which promotes membrane localization of PDK1 through its PH domain. PDK1 then
phosphorylates and activates Akt. Proteins activated by S/T phosphorylation induced by the PI3K/Akt pathway are indicated by a clear circle with a black P. Proteins
inactivated by S/T phosphorylation induced by the PI3K/Akt pathway are shown in black circles with white P. Note that depending on the phosphorylation residue,
some proteins can either be activated or inactivated by phosphorylation. Transcription factors are indicated by diamonds are similarly marked. Phosphatases are
indicated in squares and those which inhibit activity are indicated in black rectangles (PTEN and SHIP) while the PP2A phosphatase which activates Raf is shown in a
white rectangle. Arrows from phosphatases to the regulatory phosphates are indicated in open arrows.
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very intriguing.
The most common B-Raf mutation is a change at nucleotide
600 which converts a valine to a glutamic acid (V600E) [2]. This
B-Raf mutation accounts for over 90% of the B-Raf mutations
found in melanoma and thyroid cancer. It has been proposed that
B-Raf mutations may occur in certain cells, which express high
levels of B-Raf due to hormonal stimulation. Certain hormonal
signaling events will elevate intracellular cAMP levels, which
result in B-Raf activation, leading to proliferation. Melanocytes
and thyrocytes are two such cell types, which have elevated B-
Raf expression as they are often stimulated by the appropriate
hormones [121]. Moreover, it is now thought that B-Raf is the
most important kinase in the Raf/MEK/ERK cascade [2], thus
mutation at B-Raf activates downstream MEK and ERK. In
somemodels wild-type andmutant B-Raf activates Raf-1, which
in turn activates MEK and ERK [2,27,28].
In some cells, B-Raf mutations are believed to be initiating
events but not sufficient for full-blown neoplastic transforma-
tion [122,123]. Moreover, there appears to be cases where
certain B-Raf mutations (V600E) and Ras mutations are notpermitted in the transformation process as they might result in
hyperactivation of Raf/MEK/ERK signaling and expression,
which leads to cell cycle arrest [117]. In contrast, there are other
situations, which depend on the particular B-Raf mutation and
require both B-Raf and Ras mutations for transformation. The
B-Raf mutations in these cases result in weaker levels of B-
Raf activity [117,123].
Different B-Raf mutations have been mapped to various
regions of the B-Raf protein. However, the mutations at the
aforementioned 600 residue in B-Raf appear to be the most
common. This mutation (V600E) results in activation of B-
Raf and downstream MEK and ERK. Some of the other B-
Raf mutations are believed to result in B-Raf molecules with
impaired B-Raf activity, which must signal through Raf-1
[2,28]. Heterodimerization between B-Raf and Raf-1 may
allow the defective B-Raf to activate Raf-1. Other mutations,
such as D593V, may activate alternative signal transduction
pathways [2].
It has been reported that a high frequency of acute myeloid
leukemias (AML) and acute lymphocytic leukemias (ALL)
(>50%) display constitutive activation of the Raf/MEK/ERK
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While there may be some unidentified mutation at one
component of the pathway or a phosphatase which regulates
the activity of the pathway, the genetic nature of constitutive
activation of the Raf/MEK/ERK pathway is unknown. Elevated
expression of ERK in AMLs and ALLs is associated with a poor
prognosis [125]. Raf and potentially more effective MEK
inhibitors may prove useful in the treatment of a large per-
centage of AML and ALLs.
1.13. Aberrant PI3K activity, oncogenic transformation and
drug resistance
The relationship between dysregulated PI3K activity and the
onset of cancer is well-documented. For example, a mutated
version of the p85 subunit of PI3K was detected in a Hodgkin's
Lymphoma-derived cell line (CO) [126]. The PI3K p110
subunit gene PI3KCA is a frequently mutated gene in human
cancer [127]. The PI3K is the predominant growth factor-
activated pathway in LNCaP human prostate carcinoma cells
[128]. Other reports directly implicate PI3K activity in a variety
of human tumors including breast cancer [129], lung cancer
[130], melanomas [131], and leukemia [132] among others.
Further evidence supports the notion that Akt (a.k.a., protein
kinase B, PKB), a downstream kinase of PI3K, is also heavily-
involved in the malignant transformation of cells as well as the
induction of hormonal resistance [112]. Activated Akt can affect
the expression and regulation of the responses of hormone
receptors and hence lead to ineffectiveness of hormone ablation
therapies [133–135].
Activated Akt has been reported to be detected in over 50%
of primary AML samples and detection of activated Akt is
associated with a poor prognosis [125]. Furthermore, the Akt
pathway has been shown to be involved in regulation of mul-
tidrug resistance protein-1 (MRP-1) and drug resistance in
AML [136–139]. Taken together, these data endorse the
substantial role that PI3K signaling plays in oncogenesis and
drug resistance. Moreover, targeted inhibition of the central
components of this pathway appears to be an excellent choice
for future therapeutic approaches. It has been observed that
overexpression of both the Raf/MEK/ERK and PI3K/Akt
pathways in AML is associated with a worse prognosis than
overexpression of a single pathway [125]. Thus the develop-
ment of inhibitors which target both pathways or the formu-
lation of combinations of inhibitors may prove effective in the
treatment of certain cancers.
1.14. Raf and chemotherapeutic drug resistance
In certain cancer types, expression of the Raf/MEK/ERK
pathway will modulate the expression of drug pumps and anti-
apoptotic molecules such as Bcl-2 [140–145]. We have
observed that ectopic expression of Raf will increase the levels
of both the Mdr-1 drug pump and the anti-apoptotic Bcl-2
protein in breast cancer cells [144 145]. This increased
expression of Mdr-1 and Bcl-2 most likely occurs by a
transcriptional mechanism by downstream target kinases ofthe Raf/MEK/ERK pathway inducing the phosphorylation of
transcription factors which bind the promoter regions of Mdr-1
and Bcl-2 and stimulate transcription. The increased expression
of Mdr-1 and Bcl-2 is associated with the drug resistance of
these breast cancer cells.
1.15. Roles of the Raf/MEK/ERK and PI3K/Akt pathways in
growth and drug resistance of hematopoietic cells
In certain hematopoietic cell lines (FDC-P1 and TF-1), their
cytokine-dependence can be relieved by expression of activated
Raf and MEK genes [30,72,102]. Their growth is dependent
upon the presence of the activated oncogene as we have used
conditional Raf (ΔRaf:ER) and MEK (ΔMEK1:ER) oncogenes
to transform the cells to grow in the absence of the previously
required cytokine which is normally essential for their growth
and survival. This Raf/MEK dependency can be easily
determined, as removal of β-estradiol, which activates the
ΔRaf:ER or ΔMEK1:ER results in the induction of apoptosis.
Using these models (ΔB-Raf:ER, ΔRaf-1:ER, ΔA-Raf:ER and
ΔMEK1:ER), we have also determined that B-Raf, which is the
strongest inducer of downstream MEK and ERK activation, is a
potent inducer of cell cycle arrest and apoptosis, while Raf-1, A-
Raf and MEK1 are less prone to induce cell cycle arrest [70,73].
These studies indicate the Raf genes can effect cell cycle
progression and the prevention of apoptosis in hematopoietic
cells. In contrast, activated and conditional Akt and PI3K
constructs did not readily relieve the cytokine dependency of
either FDC-P1 or TF-1 cells, however, introduction of a
conditional Raf and an activated/conditional Akt or PI3K
construct would increase the frequency of cytokine-independent
cells 10- to 1000- fold depending upon the particular Raf/MEK
and PI3K/Akt combination.
The effects of activated Raf/MEK and PI3K/Akt genes on
the cytokine-dependence of FL5.12 cells was also examined
[81,146]. The cytokine-dependence of FL5.12 cells is not
readily relieved by Raf, MEK, PI3K or Akt activated proteins.
However the cytokine dependence of FL5.12 cells is relieved
when both pathways are activated in the cells, for example
introduction of an activated Raf gene (ΔRaf-1:ER) and
introduction of an activated Akt gene (ΔAkt:ER). These results
indicate that these two pathways can interact to increase the
proliferation of certain hematopoietic cells in the absence of
exogenous cytokines.
We were also interested in determining the roles of the
Raf/MEK/ERK and PI3K/Akt pathways on the induction of
drug resistance in hematopoietic cells. To address this
question we isolated doxorubicin and paclitaxel resistant
hematopoietic cells by culturing cytokine-dependent FL5.12
cells in the presence of different concentrations of doxor-
ubicin or paclitaxel in different cell/well concentrations (0.1
cell/well to 100,000 cells/well). Doxorubicin and paclitaxel
resistant hematopoietic cells were determined to express
elevated levels of activated ERK and were hypersensitive to
Raf/MEK inhibitors. The drug resistant cells were resistant to
the apoptosis inducing effects of doxorubicin and displayed a
reduced caspase 3 activation. The role of MEK in the process
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dominant negative (DN) MEK genes into the cells. Activated
MEK increased the resistance of the cells to doxorubicin by
approximately 10-fold as determined by growth and apoptosis
assays as well as the detection of cleaved caspase 3. In
contrast, introduction of DN-MEK increased the sensitivity of
the cells to doxorubicin.
The drug resistant FL5.12 cells still activate p53 after
doxorubicin treatment, suggesting that they retained a func-
tional p53 circuit. Furthermore, the drug resistance of the cells
could be increased by introduction of DN-p53 suggesting that
inhibition of the normal functions of p53, increases drug
resistance. A model for the roles of Raf/MEK/ERK, PI3K/Akt,
and p53 in the induction of drug resistance is presented in Fig. 4.
We have also developed a model for understanding the
effects of Raf and Akt on the cytokine dependence and drug
resistance of hematopoietic cells by infecting a hematopoietic
cell line, FL5.12, with retroviruses encoding conditional Raf
(ΔRaf-1:AR) and Akt (ΔAkt:ER*). The resulting cells (FL/
ΔAkt:ER*+ΔRaf-1:AR) proliferate in the absence of exo-
genous cytokines when Raf is activated by testosterone and
Akt is activated by tamoxifen. Testosterone binds the
androgen receptor (AR) domain present in ΔRaf-1:AR andFig. 4. Interactions between Raf/MEK/ERK and apoptotic pathways resulting in dru
MEK/ERK, PI3K/Akt and p53 and their effects on the induction of apoptosis are i
apoptotic regulatory molecules which exert their effects on mitochondrial membrane
molecules by Raf/MEK/ERK and PI3K/Akt is associated with prevention of the ca
stresses can result in the activation of PUMA and NOXA which can have pro-apop
would be predicted to have growth stimulatory effects. Drug resistance can result
induction and prevention of apoptosis.results in Raf activation. Tamoxifen binds the modified
estrogen receptor (ER*, mutated to bind tamoxifen 100-fold
more efficiently than β-estradiol) domain in ΔAkt:ER* which
results in Akt activation. The IC50 for doxorubicin was
increased 10-fold when Raf was activated as compared to
when Akt was activated. Furthermore, in the drug resistant
clones, Raf activation increased the IC50 for doxorubicin 80-
fold compared to Akt activation. Thus Raf induced resistance
to doxorubicin. Akt activation was not necessary for growth
in small culture volumes (100 to 200 μl cultures) over a 5-day
incubation period, however, Akt activation was necessary in
larger culture volumes (5 to 50 ml) as well as for prolonged
time periods (>5 days). Growth of the cells in the presence of
chemotherapeutic drugs was increased when both Raf and
Akt were activated, implicating a role for Akt in the drug
resistant phenotype.
The drug resistant phenotype in the FL/ΔAkt:ER*+ΔRaf-1:
AR cells was not due to the lack of a p53 response as these cells
displayed a prominent stabilization of p53 and downstream
p21Cip-1 was induced after doxorubicin treatment. These clones
displayed increased p27Kip-1 (a cyclin dependent kinase [cdk]
inhibitor) expression compared to the non-drug resistant cells.
The mechanism by which Raf-1 induces the drug resistance ofg resistance. Some of the potential downstream molecules activated by the Raf/
llustrated. The effects of Raf/MEK/ERK and PI3K/Akt on phosphorylation of
potential and the prevention of apoptosis are indicated. Phosphorylation of these
spase cascade and the induction of apoptosis. Activation of p53 by genotoxic
totic effects. Activation of p53 can also result in transcription of hbEGF which
from Raf/MEK/ERK and PI3K/Akt pathways disrupting the balance between
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phosphorylation of downstream targets which allow the cells to
grow in the presence of chemotherapeutic drugs. These targets
may be molecules involved in apoptotic pathways or may be
transcription factors which control gene expression. Alterna-
tively Raf-1 may induce the phosphorylation of proteins
involved in centrosome amplification which may occur fol-
lowing genotoxic stress.
The Raf/MEK/ERK pathway may also induce the phos-
phorylation of Bcl-2 and other key molecules involved in the
regulation of apoptosis. Certain phosphorylation events on
Bcl-2 have been associated with prolonged activation [97],
whereas other phosphorylation events on Bcl-2 induced by
chemotherapeutic drugs such as paclitaxel have been asso-
ciated with inactivation of Bcl-2 [142,147,148]. Likewise,
phosphorylation of ERK is normally associated with a pro-
liferative response. However, certain chemotherapeutic drugs
such as paclitaxel can induce the phosphorylation of ERK at
the same residues, which is associated with the prevention of
apoptosis. There is an ever growing list of apoptotic regulatory
molecules which are phosphorylated by the Raf/MEK/ERK
and PI3K/Akt pathways. This list includes Bad, Bim, Mcl-1,
Caspase 9 and Foxo3A. Foxo3A is mentioned as it is a
transcription factor which can control the expression of genes
such as Puma which regulates apoptosis through interactions
with Mcl-1 and Bax/Bak. Phosphorylation of Foxo3A by Akt
suppresses the ability of Foxo3A to induce the transcription of
Puma and other genes.
Clearly phosphorylation of these molecules involved in
apoptosis and transcription is complicated, as some phosphor-
ylation events may stimulate activity while other phosphoryla-
tion events may inhibit activity. We know very little about the
phosphatases which are responsible for removal of the
phosphate groups added by Raf/MEK/ERK and PI3K/Akt and
even less is known concerning the mechanisms which regulate
the activity of these phosphatases. Clearly such information is
very important, as many of the phosphatases which have been
identified so far, also play important roles as tumor suppressor
genes.
1.16. Expression of the Raf/MEK/ERK pathway in prostate
cancer
Increased expression of the Ras/Raf/MEK/ERK pathway has
been associated with advanced prostate cancer, hormonal
independence and a poor prognosis [149–153]. The mechan-
isms of activation of this cascade in prostate cancer have not
been well established as mutation at Ras, Raf, MEK or ERK
have not been frequently reported in prostate cancer, however,
amplification of Ras has been detected in some prostate cancers.
Alternatively, the Ras/Raf/MEK/ERK pathway could be
induced by autocrine and paracrine acting growth factors in
prostate cancer cells.
Interestingly, we observed that introduction of activated Raf
genes (Raf-1 and B-Raf) did not increase the chemoresistance of
prostate cancer cells, while introduction of activated Akt genes
did increase their chemoresistance [154,155]. Some prostatecancer cell lines such as LNCaP and PC3 cells have PTEN
mutations and express high levels of active Akt, and express
low levels of active Raf/MEK/ERK pathway members.
Hormonal independent advanced prostate cancer cell lines
such as DU145 and PC3 tend to express low levels of activated
Raf, MEK and ERK. Thus while it is logical to believe that
activation of the Ras/Raf/MEK/ERK cascade could contribute
to prostate cancer progression and hormonal independence, it
may not be as simple as one thinks as some of these established
prostate cancer lines express low levels of Raf/MEK/ERK.
Recently, a role for RKIP in prostate cancer was hypothe-
sized. Certain advanced prostate cancers express lower amounts
of RKIP than less malignant prostate cancer specimens
[156,157]. Inhibition of RKIP expression makes certain prostate
cancer cells more metastatic [156]. The mechanism responsible
for this increase in metastasis is believed to be due to the
enhanced activity of the Raf/MEK/ERK signaling pathways.
RKIP is not thought to alter the tumorigenic properties of
prostate cancer cells; rather it is thought to be a suppressor of
metastasis and may function by decreasing vascular invasion
[156].
The role of the Raf/MEK/ERK pathway in prostate cancer
remains controversial. The studies with RKIP suggest that
increasing Raf activity, by inhibition of RKIP after phosphor-
ylation by PKC, is somehow linked with metastasis in prostate
cancer [157]. However, the Raf/MEK/ERK pathway may be
shut off in advanced prostate cancer due to the deletion of the
PTEN gene, which normally regulates the activity of Akt by
counterbalancing PI3K activity [158]. In some but not all cell
lineages, Akt may inhibit Raf-1 activity by phosphorylation of
Raf-1 on S259.
The expression of the Raf/MEK/ERK pathway may be
decreased in some prostate cancer cell lines isolated from
advanced prostate cancer patients by the deletion or inactivation
of p53. p53 could influence the expression and activation of the
Raf/MEK/ERK pathway by multiple mechanisms. For example,
p53 could alter the expression of phosphatases which regulate
the activity of Raf/MEK/ERK or stimulate the transcription of
the Raf/MEK/ERK genes [159]. After DNA damage, p53 may
activate the PAC1, DUSP5 or other phosphatases which serve to
fine tune the Raf/MEK/ERK cascade. In contrast, after growth
factor stimulation, p53 may induce map kinase phosphatase
(MKP1) or other phosphatases which alter activity of the Raf/
MEK/ERK cascade. Some events associated with phosphatases
involve the removal of a phosphate group which results in
inactivation of the protein, in contrast, some dephosphorylation
events (e.g., removal of the phosphate from S259) of Raf-1 by
PP2A contributed to activation of Raf-1.
hbEGF has been observed to be a transcriptional target of
p53. p53 can transactivate hbEGF which in turn activates both
the Raf/MEK/ERK and PI3K/Akt pathways suggesting that p53
can activate survival pathways which affect the balance between
life and death in response to genotoxic stresses [159–161]. As
stated previously, Raf activates hbEGF expression in some cell
types and the effects of this induction on p53 activity are poorly
characterized. Furthermore, Akt can phosphorylate MDM-2
which in turn affects p53 activity. Clearly, the interactions
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complicated and likely feed-back upon one another. Some of the
interactions between p53 and the Raf/MEK/ERK and PI3K/Akt
pathways are illustrated in Fig. 5.
We have observed low expression of the Raf/MEK/ERK
pathway in certain prostate cancer cells (LNCaP and PC3),
which often have overexpression of activated Akt due to
deletion or mutation of the PTEN phosphatase [154,155].
Although the Raf/MEK/ERK genes are present in these cells
and Raf/MEK/ERK can be induced upon treatment with certain
chemotherapeutic drugs, their expression under normal growth
conditions are very low. This may indicate that elevated Akt
expression shuts off the Raf/MEK/ERK pathway, which may
normally induce the cell cycle arrest or senescence of prostate
cells (see Fig. 6). The situation becomes even more complicated
in advanced prostate cancer cells which have lost functional p53
activity. The expression of the Raf/MEK/ERK cascade is
detected at lower levels in these cell lines (PC3 and DU145)
than in prostate cancer lines that have both functional p53 and
PTEN (22Rv1). Introduction of wild-type p53 into PC3 and
DU145 cells increases both the sensitivity of the cells toFig. 5. Interactions between p53 and the Raf/MEK/ERK and PI3K/Akt pathways. T
Raf/MEK/ERK and PI3K/Akt pathways. These pathways are linked by complex inter
cell cycle progression as well as apoptosis. Dotted lines indicate indirect pathways.chemotherapeutic drugs and expression and activation of the
Raf/MEK/ERK cascade. Thus therapies aimed at increasing
Raf/MEK/ERK activation might be more effective in the
treatment of certain prostate cancers as they may induce
terminal differentiation, senescence or cell cycle arrest of the
cells [162–164]. In contrast, therapies aimed at decreasing Raf/
MEK/ERK activity are likely to be more appropriate for the
treatment of hematopoietic and breast malignancies where
overexpression of this cascade is associated with proliferation
and drug resistance.
In some AML patients, MDM2 is overexpressed which
enhances the tumorigenicity and the loss of apoptotic processes
resulting in a poor prognosis. When MDM2 ubiquitionates WT
p53, it becomes targeted for degradation in the proteosome. p53
controls the transcription of many genes and is critical for the
fate of the cells. Many of these targets are involved in p53-
dependent apoptotic processes (e.g., Puma and Noxo).
Recently, Andreeff and his group have observed that the
small molecular weight, membrane permeable, Nutlins bind
MDM2 and activate WT p53 and induce apoptosis. Therefore,
by using this treatment, the role of p53 is enhanced and tumorhis figure summarizes some of the complex interactions between p53 and the
actions both directly and indirectly. These interactions can result in regulation of
Fig. 6. Effects of PTEN deletion on PI3K/Akt and Raf/MEK/ERK activation in prostate cancer. PTEN deletion results in Akt activation. Akt activation can result in the
phosphorylation and inactivation of Raf. This decrease in downstream MEK and ERK activation may lead to the loss of differentiation or senescence. Lack of Raf
activation blocks p21Cip1 activation which may result in cell cycle progression. Akt activation can also result in the phosphorylation and inactivation of p21Cip1 and
Foxo3a. Fox3a normally leads to the transcription of p27zlip1 and Puma which can act to inhibit cell cycle progression and promote apoptosis. Phosphorylated Foxo3a
results in the suppression of p27kip1 and Puma transcription. Dotted lines indicate indirect pathways.
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according to this group, Nutlins are a novel therapeutic
approach in the treatment of AML and other chemorefractory
conditions [165]. Thus targeting MDM2 with Nutlins may be a
therapeutic approach in cancers which have WT p53.
1.17. Targeting the Raf/MEK/ERK pathways for therapeutic
intervention
Raf inhibitors have been developed and some are being
evaluated in clinical trials [104,166–168]. Certain Raf inhibi-
tors have been developed which are small molecule competitive
inhibitors of the ATP-binding site of Raf protein. These
inhibitors (e.g., L-779,450, ZM 336372, Bay 43-9006) bind
the Raf kinase domain and therefore prevent its activity. Some
Raf inhibitors may affect a single Raf isoform (e.g., Raf-1),
others may affect Raf proteins, which are more similar (Raf-1
and A-Raf), and while other pan Raf inhibitors may affect all
three Raf proteins (Raf-1, A-Raf and B-Raf). We have observed
that the L-779,450 inhibitor suppresses the effects of A-Raf and
Raf-1 more than the effects of B-Raf [104]. Like many Raf
inhibitors, L-779,450 is not specific for Raf; it also inhibits the
closely related p38MAPK. Likewise, Bay 49-9006 inhibits other
kinases besides Raf (e.g., VEGF-II Receptor, PDGF-R, Kit,
Flt-3). Knowledge of the particular Raf gene mutated or over-expressed in certain tumors may provide critical information
regarding how to treat the patient as some cancers which
overexpress a particular Raf gene may be more sensitive to
inhibition by agents which target that particular Raf protein.
Inhibition of certain Raf genes might prove beneficial while
suppression of other Raf genes under certain circumstances
might prove detrimental. Thus the development of unique and
broad-spectrum Raf inhibitors may prove useful in human
cancer therapy. Some of the targets which are affected by signal
transduction pathway inhibitors are illustrated in Fig. 7.
Chaperonin proteins such as 14-3-3 and Hsp90 regulate Raf
activity [13]. Raf activity is regulated by dimerization. These
biochemical properties result in Raf activity being sensitive to
drugs which block protein: protein interactions such as
geldanamycin [169]. Geldanamycin and its 17-allylamino-17-
demethoxy analog (17-AAG) are non-specific Raf inhibitors as
they also affect the activity of many proteins which are
stabilized by interaction with Hsp90. Geldanamycin and 17-
AAG are currently in clinical trials [170]. We often think of a
single Raf protein carrying out its biochemical activity.
However, Raf isoforms dimerize with themselves and other
Raf isoforms to become active. Drugs such as coumermycin,
which inhibit Raf dimerization and others such as geldanmycin,
which prevent interaction of Raf with Hsp90 and 14-3-3
proteins suppress Raf activity [13].
Fig. 7. Sites of action of small molecular weight signal transduction pathway inhibitors. Potential sites of action of small molecular weight inhibitors are indicated. In
some cases inhibitors will suppress growth, apoptotic and cell cycle regulatory pathways. This diagram serves to illustrate the concept that targeting Raf/MEK/ERK
and PI3K/Akt can have dramatic effects on many growth regulatory molecules. Proteins inactivated by S/T phosphorylation induced by the PI3K/Akt pathway are
shown in black circles with white P in a black circle.
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activation by targeting kinases (e.g., Src, PKC, PKA, PAK or
Akt) and phosphatases (e.g., PP2A) involved in Raf activation.
As mentioned earlier, some Src kinase inhibitors such as
Dastinib would be predicted to inhibit Raf activation as it
should suppress Raf-1 activation by Src. It is worth noting that
some of these kinases normally inhibit Raf activation (Akt and
PKA). A major limitation of this approach would be that these
kinases and phosphatases could result in activation or inactiva-
tion of other proteins and would have other effects on cell
physiology.
Currently it is believed that MEK1 is not frequently
mutated in human cancer. However, aberrant expression of
MEK1 is observed in many different cancers due to the
activation of the Raf/MEK/ERK pathway by upstream kinases
(e.g., BCR-ABL) and growth factor receptors (e.g., EGFR) as
well as other unknown mechanisms. Specific inhibitors to
MEK have been developed (PD98059, U0126, PD184352
(a.k.a., CI1040), PD-0325901, Array MEK inhibitors [ARRY-
142886 and others]). The successful development of MEK
inhibitors may be due to the relatively few phosphorylation
sites on MEK involved in activation/inactivation. An advan-
tage of targeting the Raf/MEK/ERK cascade is that it can be
targeted without knowledge of the precise genetic mutation,
which results in its aberrant activation. This is important as the
nature of the critical mutation(s), which leads to the malignant
growth of at least 50% of AMLs and other cancers, is not
currently known.
An advantage of targeting MEK is that Raf/MEK/ERK
pathway is a convergence point where a number of upstream
signaling pathways can be blocked with the inhibition of a
single kinase (MEK).To our knowledge, no small molecular weight ERK
inhibitors have been developed yet, however, inhibitors to
ERK could prove very useful as ERK can phosphorylate many
targets (Rsk, c-Myc, Elk, and at least 150 more). There are at
least 2 ERK molecules regulated by the Raf/MEK/ERK
cascade, ERK1 and ERK2. Little is known about the different
in vivo targets of ERK1 and ERK2. However ERK2 has been
postulated to have pro-proliferative effects while ERK1 has
anti-proliferative effects [171]. Development of specific
inhibitors to ERK1 and ERK2 might eventually prove useful
in the treatment of certain diseases.
1.18. Combination therapies to enhance toxicity
An approach, which we have been investigating recently, is
to determine whether inhibition of two signal transduction
pathways is a more effective means to induce apoptosis than
inhibiting a single signal transduction pathway. We have
observed that inhibition of the Raf/MEK/ERK and PI3K/Akt
pathways is usually a more effective means to induce apoptosis
and synergy between the two inhibitors is often observed. Many
transformed cells have elevated Raf/MEK/ERK and/or PI3K/
Akt signaling. These two pathways play prominent roles in the
promotion of growth and the prevention of apoptosis. The
PI3K/Akt pathway may be inhibited with PI3K (LY294002,
PX-866), PDK1 (OSU-03012, Celecoxib), Akt (A-443654)
inhibitors or downstream mTOR inhibitors such as rapamycin
and modified rapamycin (CCI-779). Initially mTOR inhibitors
showed much promise as PTEN is often deleted in various
tumors. However, it has been recently determined that the
mTOR pathway has a complicated feed-back loop which
actually involves suppression of Akt, hence mTOR inhibitors
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evidence has highlighted that mTOR can also be activated by
Raf/MEK/ERK [139,172,173]. This may well be another
relevant cross-talk between the Ras/Raf/MEK/ERK and the
PI3K/Akt pathways and might offer a further rationale for
treatments combining drugs which inhibit both signaling
networks.
In some cases, the precise gene responsible for driving
proliferation of the malignant cell is known (e.g., BCR-ABL
in CML, EGFR in some cases of non-small cell lung cancer,
FLT-3 in some AMLs and B-Raf in melanoma). Treatment of
some of these diseases with specific kinase inhibitors is often
effective; however, resistance to the inhibitors may develop
due to further mutations in aberrant kinases which often
prevent the signal transduction inhibitor from inhibiting the
altered kinase. In these novel “drug resistant” cases, additional
therapeutic approaches are necessary. In some of these cases, it
may be possible to inhibit the drug resistant cells with com-
binations of MEK and PI3K/Akt inhibitors. We have
observed that Imatinib resistant hematopoietic cells (which
have mutated BCR-ABL kinase) are sensitive to MEK inhi-
bitors. This result is not surprising as a Src inhibitor
(Dasatinib) is being used to inhibit Imatinib resistant cells
as they often have overexpression of an activated Src family
kinase, such as Lyn, which likely acts by inducing the Raf/
MEK/ERK cascade.
Classical chemotherapy often remains the most used anti-
cancer therapy for many different types of cancer treatment.
Drugs such as doxorubicin and taxol are effective in the
treatment of many cancers, even though in some cases drug
resistance does develop after prolonged treatment. Doxorubicin
and taxol target cellular events such as DNA replication and cell
division which are downstream of the targets of signal
transduction pathway inhibitors. Thus by combining classical
chemotherapy with targeted therapy, it may be possible to
enhance toxicity while lowering the effective concentrations of
classical chemotherapeutics necessary for effective elimination
of the particular tumor.
We have investigated the effects of combining classical
chemotherapy with signal transduction inhibitors in suppressing
the growth of hematopoietic cells which grow in response to
activated Raf and Akt or ErbB. Treatment of transformed cells
with MEK or PI3K/Akt inhibitors with either doxorubicin or
taxol resulted in a synergistic response documenting the
effectiveness of classical chemotherapy with targeted therapy.
1.19. Role of the Raf/MEK/ERK pathways in drug resistance to
reactive oxygen intermediate inducing cancer treatments
Many cancer therapies induce the generation of oxygen
radicals within cells. These therapies include treatments such as,
chemotherapeutic drugs, irradiation, and newer treatments such
as photodynamic therapy (PDT). Doxorubicin, one of the most
effective chemotherapeutic drugs against a wide variety of
cancers, works via two main mechanisms to exert anti-tumor
effects and toxicity. Doxorubicin intercalates in the DNA and
interferes with DNA polymerase with helicase activity [174]. Italso induces the production of free radicals and oxidative stress
which are involved in its anti-tumor effects [175,176]. The
generation of oxygen radicals is important for the therapeutic
effectiveness of doxorubicin because scavenging reactive
oxygen intermediates results in decreased cell killing to this
drug [177].
The initial ROS generated as a consequence of ionization
radiation is OH−, which is short-lived and only diffuses about
4 nm before reacting. Secondary ROS, produced in response to
ionizing radiation include O2− and H2O2. Studies with
fluorescent dyes demonstrated generation of ROS within cells
within 15 min after irradiation [178]. Similar to doxorubicin the
generation of oxygen radicals is important for the therapeutic
effectiveness of radiation therapy because scavenging reactive
oxygen intermediates results in decreased cell killing in response
to radiation [179].
PDT is a three-component treatment that is used for the
treatment of cancer [180]. PDT requires a photosensitizer,
molecular oxygen and a laser of a wavelength matching the
absorption spectrum of the photosensitizer (porphyrins and
porphyrin-related compounds). When a porphyrin molecule
absorbs light, it can transform an oxygen molecule to an
activated state. Similar to doxorubicin and irradiation, PDT also
requires the production of oxygen radicals to mediate some of
its anti-tumor effects [181]. Thus, three well known cancer
treatments result in the generation of reactive oxygen
intermediates. These same three treatments have also been
shown to lead to the activation of both ERK1,2 and ERK5
[182–185].
The Raf/MEK/ERK signaling pathway can play an
adaptive role in protecting cells from oxidative stress [186].
In a non-malignant murine alveolar epithelial cell line,
blocking MEK activation using the MEK inhibitor U0126
prevents hypoxia-induced Nrf2 up-regulation [186]. Deletion
of ASK1 protects cells from oxidant-induced cell death but
not death receptor-induced apoptosis [187]. Conversely,
hydrogen peroxide is capable of inducing apoptosis in
cardiomyocytes which can be increased in MEKK1 negative
cells [188]. Deletion of ASK1 protects against hydrogen
peroxide-induced apoptosis in fibroblasts and also prevents
prolonged p38 activation, suggesting an apoptotic role for p38
in response to oxidative stress [189]. Ras activation and
subsequent signaling via Rho can also activate this pathway
as does ligation of the TNF receptor [190–193]. Redox
activation of ERK5/BMK1 exhibits an anti-apoptotic effect
[54]. U0126 and PD98059 are also reported to inhibit the
activity of MEK5, the MAPKK involved in ERK5/BMK1
activation [194–196]. Suzuki et al. found that these inhibitors
decreased PC12 cell viability in response to hydrogen
peroxide treatment. This decrease in cell viability occurred
when the ERK5/BMK1 protein was completely down-
regulated using siRNA, suggesting that the effects of U0126
and PD98059 were mediated in part via ERK5/BMK1
pathway [54]. These data indicate the potential for both the
ERK1/2 and ERK5/BMK pathways to promote treatment
resistance to currently used reactive oxygen intermediate
inducing cancer treatments.
1278 J.A. McCubrey et al. / Biochimica et Biophysica Acta 1773 (2007) 1263–12842. Conclusions
Over the past 25 years, there has been much progress in
elucidating the involvement of the Ras/Raf/MEK/ERK cascade
in promoting normal cell growth as well as the etiology of
human neoplasia and the induction of chemotherapeutic drug
resistance. From initial seminal studies which elucidated the
oncogenes present in avian and murine oncogenes, we learned
that ErbB, Ras, Src, Abl, Raf, PI3K, Akt, Jun, Fos, Ets and NF-
κB (Rel) were originally cellular genes which were captured by
retroviruses. Biochemical studies defined and continue to
elucidate the roles that these cellular and viral oncogenes had
in cellular transformation. We have learned that many of these
oncogenes are connected to the Ras/Raf/MEK/ERK and PI3K/
PTEN/PDK/Akt pathways and either feed into this pathway
(e.g., BCR-ABL, ErbB) or are downstream targets, which
regulate gene expression (e.g., Jun, Fos, Ets, and NF-κB).
The Ras/Raf/MEK/ERK pathway has what often appears to
be conflicting roles in cellular proliferation, differentiation, and
the prevention of apoptosis. Classical studies have indicated
that Ras/Raf/MEK/ERK can promote proliferation and malig-
nant transformation in part due to the stimulation of cell growth
and at the same time the prevention of apoptosis. Furthermore,
an often overlooked aspect of Raf/MEK/ERK is the production
of growth factors which can stimulate growth. The latest “hot”
area of the Ras/Raf/MEK/ERK pathway is the discovery of
mutation of the B-Raf gene in human cancer, which can
promote proliferation and transformation [2]. However, it
should be remembered that only a few years ago, hyperactiva-
tion of B-Raf and Raf-1 was proposed to promote cell cycle
arrest [70,79,81]. Thus it is probably fine-tuning of these
mutations, which dictates whether there is cell cycle arrest or
malignant transformation.
Initially it was thought that Raf-1 was the most important Raf
isoform. Raf-1 was the earliest studied Raf isoform and
homologous genes are present in both murine and avian
transforming retroviruses. Originally it was shown that Raf-1
was ubiquitously expressed, indicating a more general and
important role while B-Raf and A-Raf had more limited patterns
of expression. However, it is now believed that not only B-Raf
is the more important activator of the Raf/MEK/ERK cascade
and in some cases, activation of Raf-1 may require B-Raf.
However, Raf-1 rears its head again in the cancer field by the
recent discovery that there are mutant Raf-1 alleles in certain
therapy induced t-AMLs which are transmitted in a Mendelian
fashion [116]. The role of A-Raf remains poorly defined yet it is
an interesting isoform. It is the weakest Raf kinase, yet it can
stimulate cell cycle progression and proliferation without
having the negative effects on cell proliferation that B-Raf
and Raf-1 can exert [70,81].
Activation of the Raf proteins is very complex as there are
many phosphorylation sites on Raf. Phosphorylation at different
sites can lead to either activation or inactivation. Clearly there
are many kinases and phosphatases which regulate Raf activity
and the state of phosphorylation will determine whether Raf is
active or inactive. While the kinases involved in regulation in
Raf/MEK/ERK have been extensively studied, we have only avery limited knowledge of the specific phosphatases involved in
these regulatory events.
Raf-1 has many roles, which are apparently independent of
downstream MEK/ERK. Some of these functions occur at the
mitochondria and are intimately associated with the prevention
of apoptosis. Raf-1 may function as a scaffolding molecule to
inhibit the activity of kinases which promote apoptosis.
The Raf/MEK/ERK pathway is both positively (Hsp90,
KSR, MP-1) and negatively (RKIP, 14-3-3) regulated by
association with scaffolding proteins. The expression of some
of the scaffolding proteins is altered in human cancer (e.g.,
RKIP) in some cases. Some of these scaffolding proteins (e.g.,
Hsp90) are being evaluated as potential therapeutic targets
(geldanamycin). Potential roles of Hsp90 in stabilizing
activated forms of Raf are intriguing and may allow the
evolution of activated mutant forms of Raf.
The Raf/MEK/ERK pathway is intimately linked with the
PI3K/PTEN/Akt pathway. Ras can regulate both pathways.
Furthermore, in some cell types, Raf activity is negatively
regulated by Akt indicating a cross-talk between the two
pathways. Both pathways may result in the phosphorylation of
many downstream targets and impose a role in the regulation of
cell survival and proliferation. Interestingly, Ras and Raf
mutations may not always result in similar outcomes. For
example a Ras mutation would be predicted to activate both the
Raf/MEK/ERK and PI3K pathways. Activation of PI3K/Akt
could result in the suppression of Raf/MEK/ERK. However,
mutation at either B-Raf or Raf-1 would result in only activation
of Raf/MEK/ERK.
Although we often think of phosphorylation of these
molecules as being associated with the prevention of apoptosis
and the induction of gene transcription, this view is over-
simplified. For example, in certain situations such as in
advanced prostate cancer, the Raf/MEK/ERK pathway may be
inhibited; hence the phosphorylation of Bad and CREB
normally mediated by the Raf/MEK/ERK cascade, which is
associated with the prevention of apoptosis, will be inhibited.
Likewise it is important to remember that phosphorylation at
certain protein residues will result in enhanced activity whereas
phosphorylation at different residues will result in decreased
activity. For example, phosphorylation of Bim by JNK is
associated with the promotion of apoptosis while phosphoryla-
tion of Bim by Raf/MEK/ERK or PI3K/Akt pathways is
associated with the prevention of apoptosis.
A consequence of diverse cancer therapies (chemotherapy,
radiation therapy, photodynamic therapy) is the induction of
the Raf/MEK/ERK pathway which may in some cases
provide a survival function. The mechanism of induction of
these pathways may be in part in response to the ROS
generated by the different therapies. Thus in some cases it
may be appropriate to combine these conventional therapies
with small molecular weight inhibitors which target the Raf/
MEK/ERK pathway.
Although it has been known for many years that the Raf/
MEK/ERK pathway can effect cell cycle arrest, differentiation
and senescence, these are probably some of the least studied
research areas in the field due to the often cell lineage specific
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aspect of human cancer therapy is that in some cases stimulation
of the Raf/MEK/ERK pathway may be desired to promote
terminal differentiation, while in other types of malignant
cancer cells which proliferate in response to Raf/MEK/ERK
activity, inhibition of the Raf/MEK/ERK pathway may be
desired to suppress proliferation. Thus we must be flexible in
dealing with the Raf/MEK/ERK pathway. As we learn more,
our conceptions continue to change.
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